1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66CA02AF3872951B2002587CD0040AB30
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-digital-opinion-leaders-partnering-with-vendors-lessons-learned?opendocument
18
19opendocument
2018.208.186.139
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

Medical Affairs and Digital Opinion Leaders: Partnering with Vendors and Lessons Learned

ID: 5714


Features:

10 Info Graphics

17 Data Graphics

340+ Metrics

18 Narratives


Pages/Slides: 36


Published: 2022


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs and Digital Opinion Leaders: Partnering with Vendors and Lessons Learned”

STUDY OVERVIEW

The accelerated pace of digital adoption by Medical Affairs teams has transformed the way Medical Affairs identifies and engages with a new breed of stakeholders called Digital Opinion Leaders (DOLs). While some organizations have laid the groundwork for DOL engagement, many are still catching up on this emerging phenomenon.

Best Practices, LLC undertook this research to probe how Medical Affairs teams at biopharma companies can successfully identify, engage, and collaborate with Digital Online Influencers. The study benchmarks key aspects of a DOL engagement program, including vendor management and ensuring compliant DOL engagement.

It also outlines the key strategies, success stories, and lessons learned in the realm of DOL engagement.

Benchmark data in this study is broken down into three different segments to provide deeper insights. Segmentations used in this study are as follows:

  • TBC (Total Benchmark Class) (includes all 40 survey respondents)
  • DOL Program Leaders (11 respondents)
  • DOL Program Majority (16 respondents)
  • DOL Program New-to-Space (13 respondents)

KEY TOPICS
  • Emerging Opportunities
  • Formal Partnerships with DOLs
  • Ensuring Compliance
  • Strategies and Tactics for Maximizing Medical Affairs Impact through DOL Engagement
  • Success Stories and Lessons Learned

KEY METRICS
  • Which stage of development best characterizes your organization’s medical DOL program or initiatives at present?
  • How would you describe the maturity level of your DOL program?
  • What is the value of the DOL program to your organization?
  • Which group is primarily responsible for each of the listed core DOL program areas and activities?
  • Which approach best describes how your organization manages Adverse Events monitoring across the platforms where your DOL program is active?
  • How does the medical team involved with DOLs ensure it has compliant engagement with DOLs that you are seeking to partner with?
  • Percentage of targeted DOLs who are contracted

SAMPLE KEY FINDINGS
  • Formal partnerships with DOLs: Many companies use the same contracting model for DOLs as used for KOLs, but 38% have no formal relationship in place with any DOLs as yet. On average, companies have established a formal contracting relationship with an average of 19% of all the DOLs they target for engagement. Two-thirds of immature companies have yet to formally contract with any DOLs so far.

METHODOLOGY

Best Practices, LLC engaged 40 executives from 30 leading life sciences companies in this study through a benchmarking survey. Directors and upper management executives represent 60% of the benchmark participants.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Health Care; Communications


Companies Profiled:
Alkermes; AstraZeneca; Bayer; Baxter International; Biogen; Biolink Marketing LLC; bioMerieux; Biosplice Therapeutics; Boehringer Ingelheim; Cara Therapeutics; Cipla; Eisai; Ipsen; Johnson & Johnson; Kartos Therapeutics; Kyowa Kirin; MEDiSTRAVA; Merck; Mitsubishi Tanabe Pharma; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; Purdue Pharma; Roche; Sanofi Genzyme; Santen; Sandoz; Terumo BCT: Terumo Blood and Cell Technologies; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.